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There is an urgent need for the development of alternative strategies for effective drug delivery to improve the outcome of patients
suffering fromdeadly diseases such as cancer.Nanoparticles, in particular layered double hydroxide (LDH)nanoparticles, have great
potential as nanocarriers of chemotherapeuticmolecules. In this study, we synthesized (Zn, Al)-LDHnanoparticles and report their
enhanced pH-dependent stability in comparison to the commonly used (Mg, Al)-LDH nanoparticles. Fluorescein isothiocyanate
(FITC) and valproate (VP) were intercalated into (Zn, Al)-LDH nanoparticles to study cellular uptake, biocompatibility, and drug
delivery capabilities using cultured pancreatic adenocarcinoma BxPC3 cells. Fluorescence measurements indicated that FITC-
intercalated LDH nanoparticles showed a greater degree of energy-dependent uptake rather than passive uptake by BxPC3 cells,
especially at high concentrations of nanoparticles. Tetrazolium-based colorimetric assays indicated that BxPC3 cells treated with
VP-intercalated LDH nanoparticles showed a significant reduction in cell viability along with about 30-fold reduction in IC
50
compared to the drug alone. In contrast, the non-drug-intercalated LDH nanoparticles did not affect the cell viability indicating
very low innate cytotoxicity. Our research indicates that the superior properties of (Zn, Al)-LDH nanoparticles make them ideal
candidates for further development as in vivo chemotherapy drug delivery agents.
1. Introduction
Conventional chemotherapeutic strategies involve adminis-
tration of drugs by oral ingestion or intravenous injection.
This typically results in a systemic distribution of the drugs
throughout the body with only 10–100 parts per million
reaching the desired sites, while the associated secondary
effects caused by the rest of the drugs can be serious and
sometimes life-threatening.The use of nanocarriers for deliv-
ering drugs and imaging agents can significantly improve
the pharmacokinetics, biodistribution, cellular uptake, and
therapeutic efficacywhile lowering the dosage and side effects
[1]. An ideal nanocarrier should encapsulate high doses of
drugs, remain stable under physiological conditions, protect
the drugs from degradation during the transport in the body,
and release the drug intracellularly; its surface should remain
stable and allow the conjugation of targeting moieties to
increase the specificity and effectiveness of being uptaken by
cancer cells; after biodegradation, the breakdown products
should be biocompatible. In recent years, significant progress
has been made in appropriate tailoring of the nanocarrier
with/without targetingmoieties, and nanocarrier-based ther-
apeutic/imaging agents’ delivery has shown great potential
for therapy and diagnosis [2–5]. However, diffusion and
hydrolysis controlled nanocarrier systems (such as lipid
and hydrolytically degradable polymer-based nanoparticles)
often release encapsulated agents outside the target tissues,
such as in systemic circulation [5, 6]. In general, stability
in physiological conditions, controlled release, and stimuli-
responsive triggered drug release still remain challenging for
nanocarrier development.
Among many nanocarriers (e.g., liposomes, quantum
dots, silica spheres, and magnetic nanoparticles), layered
double hydroxide (LDH) nanoparticles not only fulfill
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many of the aforementioned requirements but also have
gained particular attention due to their great flexibility in
terms of the chemical compositions, pH-dependent solu-
bility, biocompatibility, and unique anion-intercalating fea-
ture [7]. These LDH materials, based on the hydrotalcite
[Mg
6
Al
2
(OH)
16
CO
3
⋅4H
2
O] structure, consist of positively
charged hydroxide layers with electrostatically held interlayer
anions that maintain the charge neutrality. It is well known
that the interlayer anions are exchangeable, and the inter-
calation of a variety of biology-relevant, negatively charged
species such as nucleotides, fluorescent dye molecules, DNA,
vitamins, acidic drugs has been demonstrated [8–11]. The
LDH nanoparticles are usually stable under basic condi-
tions but disintegrate at lower pH (pH of 4-5) found in
the lysosome [12] so as to allow the controlled release
of intercalated species within the cell. To date, (Mg, Al)-
based and (Li, Al)-based LDH nanoparticles have been
extensively studied and numerous reports on the synthesis,
characterization, and drug delivery have been documented
[13–16]. However, several studies related to the drug release
profile have reported strong initial bursts. For example,
almost 100% Gemfibrozil was released from Gemfibrozil-
intercalated [LiAl
2
(OH)
6
] LDH within 10 minutes at pH
7, [15] and 80% of the intercalated Ibuprofen was released
from Ibuprofen-intercalated (Mg, Al)-LDH shortly after 10
minutes at pH 8 [17]. While (Mg, Al)-LDH NPs are still
being extensively explored as drug delivery vehicles [18–24],
issues related to pH-dependent stability under physiological
conditions and temporal drug-release profile alongwith other
questions related to biocompatibility, innate cytotoxicity, and
so forth have to be addressed for LDH particles to eventually
be successful for therapeutic applications.
In this study, we report the synthesis, characterization,
and in vitro drug delivery capabilities of LDH nanoparticles
based on zinc and aluminum [(Zn, Al)-LDH] as more desir-
able drug delivery nanocarrier candidates than (Mg, Al)-
LDH NPs, which have been ubiquitously reported in the lit-
erature. First, we report the synthesis of (Zn, Al)-based LDH
NPs and evaluate their pH-dependent stability compared
to that of (Mg, Al)-LDH. Next, fluorescein isothiocyanate-
(FITC-) intercalated (Zn, Al)-LDH nanoparticles were syn-
thesized and used to study cellular uptake. In order to evalu-
ate the drug delivery capability, valproate- (VP-) intercalated
(Zn, Al)-LDH nanoparticles were synthesized and character-
ized.We also propose the molecular orientation of VP within
the LDH, based on the optimized molecular geometry of VP
calculated using density functional theory and the interlayer
spacing of the VP-intercalated LDH nanoparticles observed
using X-ray diffraction (XRD). Finally, in vitro cytotoxicity
of VP-intercalated (Zn, Al)-LDH nanoparticles on cultured
pancreatic cancer cells (BxPC3) was assessed and compared
to non-drug-intercalated (Zn, Al)-LDH nanoparticles.
2. Materials and Methods
2.1. Synthesis of (Mg, Al)-LDH and (Zn, Al)-LDH
Nanoparticles. [Mg
1.85
Al(OH)
2
](NO
3
)⋅xH
2
O and [Zn
2.03
Al
(OH)
2
](NO
3
)⋅xH
2
O nanoparticles, denoted as (Mg, Al,
NO
3
)-LDH and (Zn, Al, NO
3
)-LDH, respectively, were
synthesized for the study of the pH-dependent stability using
the titration method. The details of the synthesis procedure
have been reported elsewhere [25, 26]. Briefly, 10mL metal
salt solution that contains 20mM of Zn(NO
3
)
2
⋅6H
2
O (or
Mg(NO
3
)
2
⋅6H
2
O) and Al(NO
3
)
3
⋅9H
2
O, with Zn (or Mg) to
Al molar ratio of 2, and 10mL of 40mMNaOH solution were
simultaneously added into a 3-neck flask under nitrogen
atmosphere and vigorously stirred (3000 rpm) during the
coprecipitation process. Following the constant pH synthesis
route, the pH was maintained and the final pH values of
the mixture were 5. 98 ± 0.2 for (Zn, Al, NO
3
)-LDH and
9 ± 0.2 for (Mg, Al, NO
3
)-LDH. Following hydrothermal
treatment at 85∘C for 3 h, the mixtures were cooled to room
temperature and (Zn, Al, NO
3
)-LDH/(Mg, Al, NO
3
)-LDH
nanoparticles were recovered by centrifugation.
2.2. Synthesis of FITC-Intercalated (Zn, Al)-LDH Nanopar-
ticles. Fluorescein isothiocyanate (FITC, Sigma-Aldrich, St.
Louis, MO) was intercalated into (Zn, Al, NO
3
)-LDH
nanoparticles by the ion exchange method [27]. First, the
pH of a 40mL solution of 0.833mM FITC was gradually
adjusted to neutral pH using a 0.25M NaOH solution. With
a targeted molar ratio of FITC to Al of around 0.3, an
appropriate amount of (Zn, Al, NO
3
)-LDH nanoparticles
were then dispersed into a 10mL FITC solution.The mixture
was then aged at 50∘C for a few hours; this specific temper-
ature was chosen to avoid any instability of (Zn, Al, NO
3
)-
LDH nanoparticles and to minimize coarsening [25, 26].
After cooling to room temperature, the FITC-intercalated
nanoparticles were collected by centrifugation and used for
the investigation of cellular uptake mechanisms.
2.3. Intercalation of VP into (Zn, Al)-LDH Nanoparticles
by Ion Exchange. Valproate (VP) was intercalated into
(Zn, Al, NO
3
)-LDH nanoparticles by the ion exchange
method using the VP-Na salt. First, (Zn, Al, NO
3
)-
LDH nanoparticles were dispersed in alcohol to remove
any residual water, recovered by centrifugation, and then
dried. Next, the recovered nanoparticles were equilibrated
in a 1.667mM VP-Na solution using hydroalcoholic sol-
vent (i.e., C
2
H
5
OH :H
2
O = 2 : 3 by volume) under a
nitrogen atmosphere, and the mixture was aged at 50∘C
for several hours to facilitate intercalation. After cooling,
Zn
1.91
Al(OH)
6
(NO
3
)
0.584−2y(CO3)y(VP)0.416⋅xH2O nanopar-
ticles, denoted as (Zn, Al, VP)-LDH, were separated by
centrifugation, washed in ethanol, and dried at 50∘C in
vacuum.
2.4. Optimization of VP Molecular Geometry by Computa-
tional Study. The optimization of the geometry of VP was
carried out using density functional theory. Spin-unrestricted
B3LYP method combined with 6-31G∗ basis set, as provided
in the Gaussian 03 package, was used.Themolecular orienta-
tion of the intercalated VPwithin the LDH nanoparticles was
proposed based on the optimized molecular geometry of VP
and the observed interlayer spacing of VP-intercalated LDH
nanoparticles by XRD.
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2.5. Physicochemical Characterization of LDH Nanoparticles.
Themorphology and particle size of LDH nanoparticles were
examined by bright field transmission electron microscopy
(TEM; Philips CM200 with an electron acceleration voltage
of 200 kV). The zeta (𝜁) potential was determined using
a zeta potential analyzer (PSS-NICOMP 380 with zeta
potential capability). The crystalline phase information was
obtained by powder X-ray diffraction (XRD; Rigaku D/Max-
IIB instrument with Cu-K
𝛼
radiation, 𝜆 = 0.154059 nm).The
loading capacity of VP in (Zn, Al, VP)-LDH nanoparticles
was calculated from the total carbon content, determined
using a total organic carbon analyzer (Shimadzu TOC-
VC/TN). Note that despite the meticulous synthesis condi-
tions, there were some minor CO
3
2− contaminants detected
in the XRD patterns of (Zn, Al, VP)-LDH nanoparticles,
which also contributed to the total carbon content. The
elemental compositions of the LDH nanoparticles were
determined by inductively coupled plasma atomic emission
spectroscopy (ICP; iCAP 6300 ICP Spectrometer).
2.6. Studies of pH-Dependent Aqueous Stability of (Mg, Al,
NO
3
)-LDH and (Zn, Al, NO
3
)-LDH Nanoparticles. Titration
experiments were used to study the pH-dependent stability of
LDH nanoparticles. First, given amounts of (Mg, Al, NO
3
)-
LDH and (Zn, Al, NO
3
)-LDH nanoparticles were dispersed
in deionized water. A 0.1M HNO
3
solution was then added
dropwise into the LDH NPs suspension at an addition rate
of 0.1mL per every 15min while stirring. The changes of pH
were monitored using a pHmeter (Fisher Scientific Accumet
Excel XL60).
2.7. Cell Culture. Thehuman pancreatic adenocarcinoma cell
line, BxPC3, was obtained from ATCC CRL-1687. Cells were
cultured in an incubator at 37∘C, high humidity, and 5% CO
2
in RPMI-1640 medium (Thermo Fisher Scientific, Waltham,
MA) supplemented with 10% FBS (Fisherbrand Research
Grade Serum,Thermo Fisher Scientific) and 0.2% penicillin-
streptomycin (Cambrex Bio Science, Walkersville, MD). The
cells were passaged by trypsinization using standard cell
culture protocols. All experiments were performed on cells
between passage numbers 18 and 29, and cell counts were
determined using a Muse Cell Analyzer (EMD Millipore,
Billerica, MA).
2.8. Fluorescence Analysis to Determine Energy-Dependent
Cellular Uptake of Nanoparticles. BxPC3 cells were cultured
in two 96-well tissue culture plates with 15000 cells per
well for 24 h. Prior to the treatment with nanoparticles,
one plate was preincubated for 1 hour at 4∘C (to determine
passive uptake), while the other plate was maintained at
37∘C (to determine active uptake). Cells were treated for 1
hour with various concentrations of FITC-intercalated (Zn,
Al)-LDH nanoparticles, which were also preincubated for 1
hour at either 4∘C or 37∘C. After incubation, the media with
nanoparticles were removed and the cells were washed with
PBS buffer (also preincubated at 4∘C or at 37∘C). The cells
were then lysed by the addition of 100 𝜇L/well of Pierce RIPA
lysis buffer (Thermo Fisher Scientific). Fluorescence from the
cell lysates was measured at 𝜆ex = 485 nm and 𝜆em = 520 nm
using the BioTek Synergy 2-plate reader (BioTek, Winooski,
VT).
2.9. Dose Response of BxPC3 to Valproate-Sodium (VP-Na)
and Determination of IC
50
. BxPC3 cells were seeded in a 96-
well tissue culture platewith 6000 cells perwell and incubated
for 24 hours. The cell culture media were replaced with
media containing various concentrations of VP-Na. After
72 hours, the viability of the cells was assessed using the
XTT cell viability assay kit (Gaithersburg, MD) according
to the manufacturer’s instructions. The cleavage of XTT (a
yellow tetrazolium salt) by cells leads to the formation of an
orange formazan dye which was quantified by measuring the
absorbance at 490 nm in a BioTek Synergy 2-plate reader.
All experiments were performed at least three times with
quadruple replicates for each treatment. GraphPad Prism
software was used to generate a dose response curve and
determine IC
50
of VP-Na for BxPC3 cells.
2.10. Effects of VP-Intercalated (Zn, Al)-LDH Nanoparticles.
BxPC3 cells were seeded in a 96-well tissue culture plate
with 6000 cells per well and incubated for 24 hours. The
cell culture media in the microtiter plate were replaced with
media containing various concentrations of VP-intercalated
(Zn, Al)-LDH nanoparticles. Media containing (Zn, Al)-
LDH nanoparticles intercalated with chloride or nitrate or
carbonate anionswere used as the controls to assess the effects
of the non-drug-intercalated nanoparticles. After 72 hours,
the viability of the cells was assessed using the XTT cell
viability assay, as described in Section 2.9.
3. Results and Discussion
3.1. Aqueous Stability Study and Suitability of (Mg, Al, NO
3
)-
LDH and (Zn, Al, NO
3
)-LDHNanoparticles. Theparticle size
and surface charge of nanoparticles can strongly influence
the pharmacokinetics, biodistributions, and cellular uptake
mechanisms [1]. Moreover, their aqueous stability usually
differs significantly from that of bulk materials due to the
higher chemical potential that is dictated by interfacial
tension and particle size [28]. To ensure that (Mg, Al, NO
3
)-
LDH and (Zn, Al, NO
3
)-LDH nanoparticles used for the
aqueous stability study are suitable for biomedicine, TEMwas
first used to characterize themorphology and particle size. As
shown in Figures 1(a) and 1(b), the particle sizes of (Mg, Al,
NO
3
)-LDH nanoparticles are about 30–50 nm and the sizes
of (Zn, Al, NO
3
)-LDH nanoparticles, synthesized under the
identical conditions, are larger and vary from 200 to 300 nm.
Additionally, the positive 𝜁 potential of both types of such
discoidal LDH nanoparticles, that is, +48.53mV for (Zn, Al,
NO
3
)-LDH and +44.82mV for (Mg, Al, NO
3
)-LDH, indi-
cates that their surface charge may favor the cellular uptake.
XRDwas used to identify the intercalated anionic species,
and the overall elemental compositions were determined by
ICP. Figure 1(c) shows that the experimentally determined
d
003
spacing of both LDH nanoparticles is 8.8 A˚ (2𝜃 = 10∘).
With the published data on the thickness of Brucite layer
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Figure 1: TEMbright field images of (Mg, Al, NO
3
)-LDHnanoparticles and (Zn, Al, NO
3
)-LDHnanoparticles.TheX-ray diffraction patterns
of the nanoparticles are shown in (c).
of ∼4.8 A˚, the gallery spacing was found to be ∼4 A˚, which
verifies that NO
3
− was the only intercalated species in both.
However, the relative intensities of their XRD patterns are
indicative of the higher crystallinity of (Zn, Al, NO
3
)-LDH
over (Mg, Al, NO
3
)-LDH nanoparticles. Differences in the
crystallinitymay be attributed to the fact that Zn(OH)
2
can fit
together well enough to form a more stable crystalline phase
than Mg(OH)
2
as well as the size differences between the
two nanoparticles. Since Boclair et al. reported that cation
compositions can greatly influence the formation pH of LDH
materials [29, 30], it is expected that the aqueous stability will
also be influenced.
The aqueous stability studies of (Mg, Al, NO
3
)-LDH
and (Zn, Al, NO
3
)-LDH nanoparticles at different pH were
carried out by the titration method. The pH changes were
recorded along with the addition of HNO
3
(0.1M) titrant and
the results are illustrated in Figure 2.
Initially, the pH of deionized water was measured to be
6.76. As soon as (Mg, Al, NO
3
)-LDH nanoparticles were
dispersed into deionized water, the pH increased from 6.76
and stabilized at 8.91 indicating a rapid and partial dissolution
of the nanoparticles. Since 𝐾sp (5.61 × 10
−12) of Mg(OH)
2
is
significantly higher than Al(OH)
3
(3 × 10−34), the released
OH− ions should stem from the ones bonded to Mg2+
cations. With the addition of 0.1M HNO
3
solution, the pH
gradually decreased to 5.23 due to partial dissolution of
LDH after which the slope of the titration curve remained
almost constant until pH of 4.55; the latter is indicative of
instability of the crystalline LDH and consequent dissolution
at a rapid rate. Further addition of HNO
3
resulted in an
immediate drop of pH to a steady state of 2.8. In contrast,
after the dispersion of (Zn, Al, NO
3
)-LDH nanoparticles into
deionized water, the pH decreased from 6.76 and stabilized
at 6.15, indicating the weak acidic nature of the surface that
can adsorb OH− anions from the solution. The addition of
0.1mL of HNO
3
solution instantly dropped the pH to 4.66
after which the pH was maintained upon further addition
of HNO
3
. This plateau indicates that the rapid dissolution of
(Zn,Al,NO
3
)-LDHnanoparticles occurred. Further addition
ofHNO
3
resulted in an immediate drop of pH to a steady state
of 2.8.
An ideal LDH nanocarrier composition should have
appropriate sensitivity to pH changes, that is, being stable at
physiological pH (7.2) during systemic transport but when
transfected into amalignant cell and taken up in the lysosome
it should release the drug through dissolution [2]. Because of
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Figure 2: Titration curves to assess the pH-dependent stability of
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)-LDH and (Zn, Al, NO
3
)-
LDH nanoparticles using HNO
3
(0.1M) as the titrant.
site-specific targeting of malignant cells, the LDH nanoparti-
cles will eventually be surface-functionalized with appropri-
ate moieties; this along with the stability characteristics of the
LDH will affect the pharmacokinetics, biodistributions, and
the cellular uptake mechanisms.The results of the aforemen-
tioned aqueous stability studies shed light on the suitability
of different cations in LDH-based nanocarriers. For (Mg,
Al)-based LDH nanoparticles, a couple of limitations are
evident. The observed partial dissolution when dispersed in
deionized water would lead to (a) an untimely release of the
intercalated drug at physiological pH and (b) the partial or
complete loss of surface targeting moieties. In contrast, (Zn,
Al)-based LDH nanoparticles have an excellent stability at
pH > 5. This implies that (Zn, Al)-based LDH nanoparticles
have greater stability at physiological pH and are capable
of releasing the drug intracellularly within the lysosome.
Additionally, their stable surfaces can form robust covalent
bonds with targeting moieties for improved bioavailability
and targetability. Moreover, the better crystallinity would
facilitate intercalation of negatively charged drugs via ion
exchange after synthesis. These factors along with the out-
standing biocompatibility (data shown in Section 3.3) make
(Zn, Al)-based LDH an ideal composition for incorporating
both imaging agent (FITC) and drug (VP) as in the following
studies.
3.2. Cellular Uptake of (Zn, Al)-LDH Nanoparticles. The
uptake of extracellular materials such as nanoparticles
may involve multiple mechanisms. Understanding of the
involved mechanisms in the cellular uptake is important
since the intracellular fate is usually linked to the mecha-
nism of entry. The various molecular pathways for uptake
of nanoparticles can be broadly divided into those that
require energy (active uptake) or those that do not require
energy (passive uptake). In order to determine if the uptake
of nanoparticles was an active or passive process, FITC-
intercalated LDH nanoparticles were used for the study.
Zn
2.03
Al(OH)
6
(FITC)xCl1−x⋅yH2O nanoparticles with 𝑥 ≈
0.15, denoted as (Zn, Al, FITC)-LDH, were prepared accord-
ing to the procedures described in the experimental section.
The bright field TEM micrograph for (Zn, Al, FITC)-LDH
is shown in Figure 3(a). The successful intercalation of FITC
was validated by XRD studies (Figure 3(b)). Note that, during
the preparation of the FITC solution for intercalation, depro-
tonation of FITC was monitored using a pH electrode filled
with a saturated KCl solution, which led to the replacement
of the intercalated NO
3
− by Cl− ions. While the primary
XRD peaks at 2𝜃 of 11.47∘ (d
003
= 7.7 A˚) and 23.4∘ (d
006
=
3.8 A˚) correspond to the intercalated Cl− anion, the extra
hump centered at 2𝜃 of 5.18∘ is indicative of an expansion
(d
003
= 17.05 A˚) due to the presence of the intercalated FITC.
Also by subtracting the double hydroxide layer thickness of
about 4.8 A˚ [31], an interlayer gallery spacing of ∼12.25 A˚
corresponds to the size of the intercalated FITC.
Cell cultures incubated at either 37∘C (normal cell culture
temperature) or 4∘C (lower temperature) were treated with
(Zn, Al, FITC)-LDH. Since energy-dependent pathways tend
to be inhibited at lower temperatures, this allowed us to
assess the energy dependence on the cellular uptake of
nanoparticles. Relative fluorescence measured from cells
(Figure 4) shows that the uptake of nanoparticles involves a
combination of both active and passive processes. However,
at higher concentrations (5mM), there appears to be a
greater dependence (about 50% higher) on energy-mediated
pathways for the entry of the nanoparticles into the cell.
Several other studies have utilized endocytosis inhibitors
such as genistein, chlorpromazine, and nocodazole to inves-
tigate the specific active pathways involved in the cellular
uptake of nanoparticles. We were not able to clearly dis-
tinguish between the different endocytosis pathways for the
uptake of (Zn, Al, FITC)-LDH nanoparticles using these
inhibitors (data not shown). Several other reports have also
indicated ambiguity with their uptake data while using these
inhibitors [32].
3.3. Effect of VP on Cultured Pancreatic Cancer BxPC3 Cells.
Valproic acid (VPA, 2-propylpetanoic acid) is a short chain
fatty acid that has been approved by the FDA for the
treatment of epilepsy, bipolar disorders, and migraine and
has been clinically used for schizophrenia. More recently
there has been an interest in VPA as an anticancer drug
and it is currently being assessed in clinical trials for the
treatment of different tumors [33]. While the molecular
mechanisms by which VPA can act as anticancer drug are
not fully understood, its ability to inhibit histone deacetylases
and activate notch-1 signaling seems to be important [34].
The ability of VPA to inhibit the proliferation of cultured
pancreatic cancer cells is particularly interesting since this
is a deadly disease with an extremely high rate of mortality.
When we tested the antiproliferative effects of VP-Na on the
cultured human pancreatic adenocarcinoma cell line BxPC3,
we found that it is effective at high concentrations (IC
50
of
63.21mM, Figure 5). Other studies have shown that this effect
6 Journal of Nanotechnology
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Figure 3: TEM bright field micrograph of Zn
2
Al(OH)
6
(FITC)xCl1−x⋅xH2O, 𝑥 ≈ 0.15, in (a); the corresponding XRD pattern is shown in (b),
with a slow scan at 2-𝜃 between 2.5 and 7.5.
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Figure 4: Assessment of energy dependence of the uptake of
nanoparticles. Fluorescence from BxPC3 cell treated with (Zn,
Al, FITC)-LDH nanoparticles at either 37∘C (active uptake) or at
4∘C (passive uptake). 𝑥-axis represents the concentration of the
nanoparticles in terms of Al content.
is primarily due to the downregulation of the Alzheimer
amyloid precursor protein [35].
Meanwhile the high IC
50
in vitro on cultured cells
indicates that a very high dose is required in vivo for effective
chemotherapy. This is a cause for concern since the drug has
a high risk of side effects, especially due to its psychoactive
properties. A promising strategy to overcome this challenge
and improve the therapeutic index of such drugs is the use of
LDHnanoparticles for drug delivery.Hence, for this study, we
utilized VP for proof-of-concept experiments to demonstrate
the utility of (Zn, Al)-LDH nanoparticles for drug delivery to
cultured pancreatic cancer BxPC3 cells.
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Figure 5: Dose response of the viability of BxPC3 cells to various
concentrations of valproate-sodium to determine IC
50
of the drug.
Note that (Zn, Al)-LDH nanoparticles were not used for drug
delivery for this experiment.
3.4. Characterization of VP-Intercalated (Zn, Al)-LDH
Nanoparticles. Valproate-intercalated (Zn, Al)-LDH nano-
particles were synthesized and in vitro toxicity studies
were carried out using pancreatic cancer cells, and the
results were compared to using Na-VP alone. The long
hydrophobic tail of VP was originally designed to balance
the partition coefficient and increase the lipophilicity and
the penetration into the cell. However, it was found that,
in aqueous medium, VP self-organize to form micelles,
which could partially dissolve LDH materials by capturing
the metal ions. Consequently, it was necessary to use an
alcohol-aqueous solution to attain a higher solubility of VP
during ion exchange and thereby prevent the formation
of micelles and dissolution of the LDH nanoparticles. 𝜁
potential of (Zn, Al, NO
3
)-LDH nanoparticles was measured
to be 48.53mV, but, after the intercalation of VP, 𝜁 potential of
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Figure 6: TEM bright field micrograph of Zn
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O nanoparticles is shown in (a), and XRD analysis
before and after intercalation shown in (b) shows the partial replacement of the intercalated NO
3
− by VP and CO
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2− (as minor contaminants).
Zn
1.91
Al(OH)
6
(NO
3
)
0.584−2y(CO3)y(VP)0.416⋅xH2O (hereon
denoted as (Zn, Al, VP)-LDH) nanoparticles decreased
to 37mV, indicating that some surface adsorption of VP
had occurred. The TEM micrograph in Figure 6(a) shows
that the particle size of (Zn, Al, VP)-LDH NPs is ∼350–
500 nm, formed due to minor agglomeration of primary
nanoparticles (∼150 nm) due to lowered 𝜁 potential. The
XRD patterns before and after the intercalation, shown in
Figure 6(b), validate the successful intercalation of VP, with
some minor contamination of the intercalated CO
3
2−. The
significant expansion of the interlayer spacing occurred due
to the intercalation of VP, and the observation of two peaks
at 2𝜃 of 3.74∘ and 4.72∘ suggests that intercalated VP can exist
in two different forms. By assuming a thickness of the double
hydroxide layer to be ∼4.80 A˚ [31], the interlayer spacings are
then 18.8 A˚ and 13.9 A˚, respectively.
To determine the molecular orientation of the interca-
lated VP that gives rise to these interlayer spacings, the
geometry of VP was first optimized by the spin-unrestricted
B3YLP method, using diffuse function basis set of 6-31G∗,
and the optimized geometry is illustrated in Figure 7(a).
The data suggests that VP is intercalated in double layer
orientation, but, as depicted in Figure 7(b), the hydration
levels may vary.
3.5. Delivery of Valproate to Pancreatic Cancer BXPC3 Cells
Using Valproate-Intercalated (Zn, Al)-LDH Nanoparticles. In
order to assess the utility of the newly synthesized (Zn, Al)-
LDH nanoparticles for drug delivery, cultured pancreatic
cancer BxPC3 cells were treated with VP-intercalated LDH
nanoparticles. It appears that the drug-intercalated nanopar-
ticles are stable in cell culture media and can be efficiently
uptaken by the cells leading to delivery of large doses of
the drug. While the positive surface charge of (Zn, Al, VP)-
LDH nanoparticles may provide excellent affinity to the cell
surface, the exact molecular mechanism for the uptake of the
LDH nanoparticles into the cell was not determined in this
study. A significant reduction in the amount ofVP required to
lower cell viability was observed when the drug was delivered
using the nanoparticles, leading to an approximately 30-fold
reduction in IC
50
from63.21mM to about 2mM in pancreatic
cancer BxPC3 cells.
(Zn, Al)-LDH nanoparticles intercalated with carbonate
(Zn, Al, CO
3
) or chloride (Zn, Al, Cl) or nitrate (Zn,
Al, NO
3
) anions were used as the controls to study the
effect of nanoparticles without the drug on the cancer cells.
The corresponding XRD and TEM micrographs are shown
in Figure S1 in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/350370. Figure 8 shows the
effects of (Zn, Al, VP)-LDH nanoparticles along with the
control nanoparticles on BxPC3 cells. The control nanopar-
ticles did not significantly lower the viability of BxPC3 cells
in the range of concentrations tested. The lack of cytotoxicity
may be due to the fact that (Zn, Al)-LDH nanoparticles are
synthesized from inorganic ionswhich are not toxic to human
cells at low concentrations. The excellent biocompatibility
indicates that any side effects due to the nanoparticle itself
are likely to be minimum when it is used in vivo.
Thehigh stability, excellent biocompatibility, and superior
in vitro drug delivery properties of (Zn, Al)-LDH nanoparti-
cles show promise that these nanoparticlesmay retain their in
vivo efficacy. In this study, VP was used as proof-of-concept
to demonstrate the utility of (Zn, Al)-LDH nanoparticles for
drug delivery. While VP may not prove to be the ideal drug
for cancer therapy, our results indicate that (Zn, Al)-LDH
nanoparticles have great potential for the delivery of various
chemotherapeutic agents. Further modification of (Zn, Al)-
LDH nanoparticles to include cancer cell targeting ligands
on the surface is likely to enhance drug delivery and further
minimize off-target effects.
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Figure 7: (a) shows GaussView 03 generated 3D representation of the optimized geometry of VP by spin unrestricted B3YLP method using
6-31G∗ basis set. In (b), the intercalated VP are proposed to be in double layer orientation with different hydration levels according to the
interlayer spacing calculated from XRD pattern and the optimized geometry of the VP.
4. Conclusions
In this study, it was found that (Zn, Al)-LDH nanoparticles
have excellent physicochemical properties as ideal nanocar-
riers for pH-sensitive drug delivery. In comparison to (Zn,
Al)-LDH nanoparticles, (Mg, Al)-LDH nanoparticles were
observed to have poor stability at pH lower than 8.91. This
may, in part, explain the rapid release of the intercalated
drugs under physiological conditions (pH ∼7.2) from (Mg,
Al)-LDH nanoparticles. In contrast, (Zn, Al)-based LDH
nanoparticles showed an excellent stability above pH 4.66,
which may indicate greater stability under physiological
conditions leading to selective release of the drug upon reach-
ing the lysosomes within cells. Such a greater stability also
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Figure 8: The effect of (Zn, Al)-LDH nanoparticles intercalated
with valproate (Zn, Al, VP) on the viability of cultured pancreatic
cancer BXPC3 cells. The effect of nanoparticles without the drug
was assessed by using (Zn, Al)-LDH nanoparticles intercalated with
either carbonate (Zn, Al, CO
3
), chloride (Zn, Al, Cl), or nitrate (Zn,
Al, NO
3
) anions.
makes them better candidates for targeted drug delivery by
incorporating cell targeting ligands onto the surface. The use
of (Zn, Al, FITC)-LDH nanoparticles revealed that energy-
dependent cellular uptake mechanisms are more active at
higher nanoparticle concentrations. When the ability of (Zn,
Al)-LDH nanoparticles to deliver VP into pancreatic cancer
BxPC3 cells was tested, we found a 30-fold reduction in
IC
50
value of VP. In addition to their excellent drug delivery
capabilities, (Zn, Al)-based LDH nanoparticles were also
found to be highly biocompatible since control nanoparticles
(without drug intercalation) were found to have minimal
cytotoxicity.
Although VP was used as proof-of-concept to demon-
strate the utility of (Zn, Al)-LDH nanoparticles for drug
delivery, results from the current work indicate that these
nanoparticles have excellent utility for the delivery of several
other chemotherapeutic agents. In addition, the ability of (Zn,
Al)-LDH nanoparticles to intercalate and deliver magnetic
resonance imaging contrast agents makes them suitable for
theranostic applications. The biocompatibility and in vivo
utility of (Zn, Al)-LDH nanoparticles for drug delivery will
have to be tested in animal models to assess the potential for
ultimate use in patients.
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